These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The effect of a year of highly active antiretroviral therapy on immune reconstruction and cytokines in HIV/AIDS patients.
    Author: Yao Y, Luo Y, He Y, Zheng Y, Zhang Q, Zhou H, Zeng S, Chen Z, He B, He M.
    Journal: AIDS Res Hum Retroviruses; 2013 Apr; 29(4):691-7. PubMed ID: 23151174.
    Abstract:
    To investigate the effect of a year of highly active antiretroviral therapy (HAART) on immune reconstruction and cytokine production in HIV/AIDS patients, 35 AIDS patients were recruited for HAART treatment and 35 healthy volunteers were assigned as controls. The dynamic changes in HIV load, blood T cell subset counts, as well as interleukin (IL)-12, interferon (IFN)-γ, and interferon-inducible protein-10 (IP-10) levels in AIDS patients were evaluated before HAART and at 6 and 12 months after therapy. Our results revealed that HIV virus load in HIV/AIDS patients was reduced below the detectable limit after patients received 6 months of HAART. CD3(+)CD4(+), CD4(+)CD45RA(+)62L(+), and CD4(+)CD45RO(+) T cells were found to be significantly decreased in HIV/AIDS patients compared to the healthy controls, but increased after HAART. CD3(+)CD8(+) and CD8(+)CD38(+) cells were found to be increased in HIV/AIDS patients but decreased after HAART. Plasma IL-12 and IFN-γ levels were lower but IP-10 level was higher in AIDS patients compared to controls. HAART significantly improved IL-12 and IFN- γ levels but reduced IP-10 level in AIDS patients (p<0.01). CD4(+)CD45RA(+)62L(+) and CD4(+)CD45RO(+) T cells were positively correlated with plasma IL-12/IFN-γ levels (p<0.05), but negatively correlated with plasma IP-10 level. However, CD3(+)CD8(+) cells were negatively correlated with plasma IL-12 and IFN-γ levels, but positively correlated with IP-10 level (p<0.05). HAART benefits HIV/AIDS patients by not only inhibiting virus replication but also by contributing to immune reconstruction, such as restoring subsets of T cells and adjusting cytokine production in HIV/AIDS patients.
    [Abstract] [Full Text] [Related] [New Search]